2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 471

When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 271

Who Prescribed Which Osteoporosis Medication to Whom

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 240

Whom Do Patients with Fibromyalgia Turn to for Emotional Support?

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 169

Wikipedia as a Source of Health Information for the Public: Systematic Analysis of Quality and Readability of 8 Common Rheumatic Diseases Articles

Education/Community Programs Poster – ARP

9:00AM-11:00AM: Abstract Number: 497

Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 418

Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 163

Workforce Survey: Career Trends of Combined Adult and Pediatric Rheumatology Fellowship Graduates

Education Poster

9:00AM-11:00AM: Abstract Number: 567

Worse Outcomes for Female Patients with Axial Spondyloarthropathy

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 395

Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis

Muscle Biology, Myositis & Myopathies Poster I

11:00AM-12:30PM: Abstract Number: 806

A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease

3S032: Plenary I (805–809)

11:00AM-12:30PM: Abstract Number: 807

Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

3S032: Plenary I (805–809)

11:00AM-12:30PM: Abstract Number: 808

Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial

3S032: Plenary I (805–809)

11:00AM-12:30PM: Abstract Number: 805

Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities

3S032: Plenary I (805–809)

11:00AM-12:30PM: Abstract Number: 809

TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)

3S032: Plenary I (805–809)

11:30AM-1:30PM: Abstract Number: PP06

Art for Arthritis: A New Approach

Patient Perspectives Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].